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symptoms in selected patients with severe heteroge-
neous emphysema. However, limited data exist regard-
ing long-term outcome after LVRS. Our group and oth-
ers, have shown that bilateral LVRS produces greater
short-term improvement in FEV1 than do unilateral sta-
ple or Nd:YAG volume reduction procedures.1,2
Therefore, we have adopted bilateral thoracoscopic sta-
ple LVRS as our standard approach to bilateral hetero-
geneous, severe emphysema. However, the ultimate
value of bilateral versus unilateral LVRS will depend on
the long-term results.
Longer term survival outcomes after unilateral and
bilateral LVRS procedures have not been reported. The
purpose of this study was to compare 2-year mortality
between bilateral and unilateral thoracoscopic LVRS in
a large group of patients operated on by a single group
of thoracic surgeons at one medical center.
M ultiple studies have demonstrated that lung volumereduction surgery (LVRS) provides immediate
improvement of pulmonary function and dyspnea
Objective: Bilateral staple lung volume reduction surgery (LVRS) imme-
diately improves pulmonary function and dyspnea symptoms in patients
with advanced heterogeneous emphysema to a greater degree than do
unilateral procedures. However, the long-term outcome after these sur-
gical procedures needs to be critically evaluated. We compare 2-year
survival of patients who underwent unilateral versus bilateral video-
assisted LVRS in a large cohort treated by a single surgical group.
Methods: The cases of all 260 patients who underwent video-assisted tho-
racoscopic stapled LVRS from April 1994 to March 1996 were analyzed
to compare results after unilateral versus bilateral procedures. Overall
survival was calculated by Kaplan-Meier methods; Cox proportional
hazard methods were used to adjust for patient heterogeneity and base-
line differences between groups. Results: Overall survival at 2 years was
86.4% (95% CI 80.9%-91.8%) after bilateral LVRS versus 72.6% (95%
CI 64.2%-81.2%) after unilateral LVRS (P = .001 for overall survival
comparison). Improved survival after bilateral LVRS was seen among
high- and low-risk subgroups as well. Average follow-up time was 28.5
months (range, 6 days to 46.6 months) for the bilateral LVRS group and
29.3 months (range, 6 days to 45.0 months) for the unilateral LVRS
patients. Conclusions: Comparison of unilateral versus bilateral thoraco-
scopic LVRS procedures for the treatment of emphysema reveals that
bilateral LVRS by video-assisted thoracoscopy resulted in better overall
survival at 2-year follow-up than did unilateral LVRS. This survival
study, together with other studies demonstrating improved lung func-
tion after bilateral LVRS, suggests that bilateral surgery appears to be
the procedure of choice for patients undergoing LVRS for most eligible
patients with severe heterogeneous emphysema. (J Thorac Cardiovasc
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SURVIVAL AFTER UNILATERAL VERSUS BILATERAL LUNG VOLUME REDUCTION SURGERY FOR
EMPHYSEMA
Methods
Methods for patient selection, preoperative analysis, surgi-
cal procedures, and follow-up studies for patients undergoing
bilateral and unilateral thoracoscopic staple LVRS in this
clinical program have been previously described.1,2
All patients who underwent unilateral or bilateral thoraco-
scopic staple LVRS at Chapman Medical Center from April
1994 to March 1996 were included in this evaluation.
Baseline characteristics of all study patients appear in Table I.
Patients underwent baseline complete pulmonary function
testing, including: spirometry, gas exchange measures (room
air arterial blood gas measurement, DLCO), plethysmogra-
phy, and gas dilution lung volumes. Maximum inspiratory
and expiratory flow volume curves and thoracic gas volume
were measured in a plethysmograph (Collins/Cybermedic
Classic TCI and Body Plethysmograph; Warren E. Collins
Inc, Braintree, Mass) and compared with predicted values, as
previously described.1,3 All patients underwent LVRS at
Chapman Medical Center by one or both of 2 thoracic sur-
geons in the research group (R.J.M., R.J.F.). No procedures
were performed at any other center in this protocol.
Repeated pulmonary function studies were requested from
patients 3 months postoperatively, at 6 months, and at approx-
imately 6-month intervals thereafter. Whenever possible,
repeated spirometry was performed at least once at Chapman
Medical Center within 3 months of surgery, but subsequent
spirometry data were obtained from the referring site.
Informed consent for surgery and preoperative evaluation was
obtained from all patients. Despite maximal medical manage-
ment, all patients were markedly symptomatic. Chest radio-
graphs showed hyperexpansion of the thorax, with flattening
or inversion of the diaphragms.
Contraindications to surgery included current cigarette
smoking, age greater than 80 years, severe cardiac disease
(congestive heart failure, significant coronary or valvular dis-
ease), history of cancer within the last 5 years, ventilator
dependency, or prior thoracic surgery. Relative contraindica-
tions included age older than 75 years, severe anxiety, severe
depression, or CO2 retention with resting PaCO2 higher than
55 mm Hg.1,3
To be accepted for the procedure, the patient had to have a
pattern of emphysema, seen on computed tomography (CT),
that was severe and heterogeneous. Radionuclide lung perfu-
sion scans were also used to confirm the heterogeneous pat-
tern of emphysema.1,3
Thoracoscopic LVRS operative methods. Operative pro-
cedures for thoracoscopic staple LVRS have been described
previously.1,2 All patients underwent video-assisted thoracic
surgery while under paralyzed (pipecuronium) general anes-
thesia (isoflurane), with use of a left-sided double-lumen tube
(Mallincrodt Anesthesia, St Louis, Mo).
Procedures were performed by one surgical group (R.J.M.,
R.J.F., M.B.) with the patient in the lateral decubitus position.
The trocar and thoracoscope were placed through the 10th
intercostal space in the posterior axillary line. Three addi-
tional 1- to 2-cm incisions were made for standard instru-
ments. Patients undergoing bilateral thoracoscopic proce-
dures were turned to the contralateral decubitus position for
separate sterile preparation and draping after the procedure
on the initial side was completed. 
Preoperative lung CT scans and ventilation-perfusion ( ·V/Q· )
scans were used to identify areas of dysfunctional or degen-
erated lung targeted for resection with the staples.1,2 Ring for-
ceps were used to manipulate the lung into a 60-mm endo-
scopic stapler (ELC 60; Ethicon, Cincinnati, Ohio) with
bovine pericardium (Peristrips; Biovascular, Saint Paul,
Minn) or bovine collagen matrix (Instat; Johnson and
Johnson, New Brunswick, NJ) used to buttress the staples.
The staples were fired an average of 15 times for bilateral
operations. Typically, approximately half of the upper lobe
was resected in patients with upper lobe disease.
Survival. Survival status was assessed for all patients by
contacting them directly or their referring physicians between
March and June 1998. The latest date of known survival was
recorded, and the date and cause of death (if known) were
recorded for patients who had died. Six patients had under-
gone a second LVRS procedure. These patients’ records were
coded for their first surgical procedure with all available fol-
low-up in accordance with “intent-to-treat” methods. Patients
with survival beyond Feb 28, 1998, were censored as of Feb
28, 1998, for purposes of survival analysis.
Response assessment. To be included in the follow-up
evaluation analyses of pulmonary function in this study,
patients were required to have follow-up pulmonary function
testing at 2 years ± 6 months after surgery. To be included in
the follow-up evaluation analyses of mortality in this study,
patients were required to have had their surgical procedure
between the period of April 1994 and March 1996. All study
patients had known mortality or survival information.
Statistical analysis. Baseline characteristics for patients
undergoing unilateral or bilateral surgery are described in
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Table I. Means and standard error of the mean for
baseline characteristics of all study patients
Bilateral Unilateral 
Characteristic VATS* VATS* P value
No. 159 110
Age 67.14 ± 6.73 68.39 ± 7.51 .16
FVC 2.00 ± 0.73 2.11 ± 0.71 .17
FEV1 0.64 ± 0.25 0.70 ± 0.29 .13
RV 4.54 ± 1.41 4.80 ± 1.21 .13
TLC 7.15 ± 1.74 7.54 ± 1.42 .08
RAW 5.37 ± 2.22 4.91 ± 1.93 .12
RV/TLC 0.67 ± 0.10 0.72 ± 0.30 .10
DLCO 5.31 ± 2.84 4.75 ± 2.63 .07
Po2† 64.80 ± 12.43 60.40 ± 12.30 .008
Pco2 43.17 ± 7.33 44.81 ± 9.17 .01
FVC, Forced vital capacity; FEV1, forced expiratory volume in 1 second; RV,
residual volume; TLC, total lung capacity; RAW, airway resistance; DLCO,
diffusing capacity for carbon monoxide.
* The pulmonary function tests are plethysmographic. Values are expressed as
mean ± SD.
† Significant value between unilateral and bilateral VATS, P ≤ .05.
terms of means and standard error of the mean. Comparison
of differences between patients before and after surgery is
determined by 2-tailed paired t tests. Differences between
surgery groups at baseline are tested by 2-tailed t tests for
continuous variables or chi-square tests for categorical vari-
ables. Overall survival is calculated by using the Kaplan-
Meier survival analysis. Differences between survival curves
for unilateral and bilateral surgery are tested using the log-
rank test. To examine the influence of potential confounders
and control for baseline differences in pulmonary function,
we used stratified Kaplan-Meier methods. Patients were strat-
ified into 2 groups by baseline characteristics, using the cut
points forced expiratory volume in 1 second (FEV1; 0.50
L/s), PaO2 (55 mm Hg), age (70 years), forced vital capacity
(FVC; 1.5 L), total lung capacity (TLC; 8.5 L), residual vol-
ume (RV; 5.5 L), and surgery date (eg, May 1, 1995). Cut
points for FEV1, PaO2, and age were chosen according to an
earlier published definition of high-risk subgroups.4 Cut
points for FVC, TLC, and RV were arbitrarily defined as the
limit of the highest risk quartile after finding that the cutoffs
for FEV1 and PaO2 approximated the lower limits of the high-
est risk quartile. Differences between the bilateral and unilat-
eral surgery groups after stratification was taken into account
were tested with the log-rank test.
In addition, we used Cox proportional hazards methods to
test the significance of differences between surgery groups
after simultaneously adjusting for baseline differences
between patients. To adjust for patient heterogeneity and
baseline differences between the surgical groups, we calcu-
lated a propensity score to be included as a covariant in the
Cox regression analysis.5 The propensity score, calculated by
logistic regression with “surgery type” used as the dependent
variable, represents the likelihood for a patient with specified
baseline values to have unilateral, versus bilateral, surgery.
Independent variables included in the estimation of propensi-
ty scores are age, sex, FEV1, PaO2, FVC, TLC, RV, and
surgery date. For 33 patients with missing data, data were
imputed by regressing that variable against all variables with
acceptable values for that individual in a stepwise procedure.
Three patients had insufficient data for imputation.
Covariables included in the Cox regression analysis are
propensity score, age, sex, FEV1, PaO2, FVC, TLC, RV, and
surgery date. Analyses were conducted by using the Systat
7.0 for Windows and BMDP 7.0 statistical software packages
(SPSS Inc, Chicago, Ill).
Rehabilitation. Patients did not receive preoperative reha-
bilitation at Chapman Medical Center before undergoing
LVRS. All patients underwent a regimen of pulmonary reha-
bilitation at Chapman Medical Center immediately following
hospital discharge after surgery. The rehabilitation consists of
a 10-day outpatient regimen involving a multidisciplinary
approach with nursing, respiratory, dietary, nutritional, psy-
chosocial, occupational, and physical therapy. Patient educa-
tion, physical exercise (walking, flexibility, and strengthen-
ing), self-monitoring, breathing retraining, and bronchial
hygiene instruction are included.
Results
Composite results in all patients. A total of 260
patients underwent LVRS procedures in this program
during the analysis interval: 106 patients underwent
unilateral thoracoscopic staple LVRS and 154 patients
bilateral thoracoscopic staple LVRS. In addition, 6
patients had a second LVRS procedure. Four patients
initially underwent unilateral LVRS followed by a sec-
ond unilateral surgery. One patient underwent bilater-
al LVRS after an initial unilateral procedure. One
patient underwent bilateral surgery followed by a sec-
ond bilateral LVRS. Patients who underwent a second
LVRS procedure were analyzed according to the initial
intent-to-treat and were classified by the first surgery
only.
Unilateral thoracoscopic staple LVRS–treated
patients. Overall survival at 1 and 2 years was 81.1%
(95% CI 73.6%-88.6%) and 72.6% (95% CI 64.2%-
81.2%), respectively, after unilateral thoracoscopic
LVRS (Fig 1, Table II).
Bilateral thoracoscopic staple LVRS–treated
patients. Overall survival at 1 and 2 years was 90.3%
(95% CI 85.6%-94.9%) and 86.4% (95% CI 80.9%-
91.8%), respectively, after bilateral thoracoscopic
LVRS (P = .001 for overall survival comparison
between unilateral and thoracoscopic LVRS).
Average follow-up time was 28.5 months (range, 6
days to 46.6 months) for the bilateral LVRS group and
29.3 months (range, 6 days to 45.0 months) for the uni-
lateral patients. During this period, 27% (29/106) of
unilaterally treated study patients died of respiratory
failure (Table III). In comparison, 6% (10/154) of bilat-
erally treated patients died of respiratory failure.
Risk subgroup analysis. Previously identified risk
factors for poor 2-year survival after bilateral LVRS6
(age > 70 years, PaO2 ≤ 55 mm Hg, FEV1 ≤ 0.5) were
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Fig 1. Overall Kaplan-Meier survival analysis 2 years after
surgery, unilateral versus bilateral LVRS.
examined for their effects on outcome in unilateral,
compared with bilateral, LVRS patients.
Thirty-two percent (30/94) of patients who under-
went unilateral LVRS had baseline hypoxemia defined
as PaO2 ≤ 55 mm Hg, compared with 21% (32/149) of
patients who underwent bilateral LVRS. When strati-
fied by baseline PaO2, survival was better for bilateral
LVRS patients (log-rank test, P = .02; Fig 2, Tables IV
and V).
Forty-three percent (45/104) of patients who under-
went unilateral LVRS were more than 70 years of age,
compared with 32% (50/154) of bilateral LVRS
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Table II. Overall survival
6 mo 182 d 12 mo 365 d 18 mo 547 d 24 mo 730 d 36 mo 1095 d
Unilateral LVRS
Cumulative survival 0.85 0.81 0.77 0.73 0.63
95% CI 0.78-0.92 0.74-0.89 0.69-0.85 0.64-0.81 0.53-0.72
Cumulative deaths 16 20 24 29 39
Remaining at risk 90 86 82 77 48
Bilateral LVRS
Cumulative survival 0.94 0.9 0.88 0.86 0.81
95% CI 0.90-0.97 0.86-0.95 0.83-0.93 0.81-0.92 0.74-0.88
Cumulative deaths 10 15 18 21 27
Remaining at risk 144 139 136 123 22
Table III. Mortality of all patients
Unilaterally treated patients (%) Bilaterally treated patients (%)
Cause of death <30 d >30 d Overall <30 d >30 d Overall
Respiratory failure 3 26 29 2 8 10
Pneumonia 0 2 2 0 3 3
Pneumonitis 0 0 0 0 1 1
Pulmonary embolism 0 0 0 0 1 1
Pulmonary bleb rupture 1 1 2 0 0 0
Cardiac arrest or MI 1 3 4 1 3 4
Congestive heart failure 0 1 1 0 1 1
AAA 0 1 1 0 1 1
Acute abodomen 0 0 0 1 0 1
Cancer 0 1 1 0 1 1
Colitis 0 1 1 0 0 0
Unspecified infection 0 0 0 0 1 1
Amyotrophic lateral sclerosis 0 0 0 0 1 1
Head trauma 0 0 0 0 1 1
Unknown 0 1 1 0 1 1
MI, Myocardial infarction; AAA, abdominal aortic aneurysm.
Table IV. PaO2 ≤ 55 mm Hg (torr)
6 mo 182 d 12 mo 365 d 18 mo 547 d 24 mo 730 d 36 mo 1095 d
Unilateral LVRS
Cumulative survival 0.73 0.67 0.57 0.5 0.32
95% CI 0.58-0.89 0.50-0.84 0.39-0.74 0.32-0.68 0.15-0.49
Cumulative deaths 8 10 13 15 20
Remaining at risk 22 20 17 15 5
Bilateral LVRS
Cumulative survival 0.81 0.81 0.75 0.72 0.59
95% CI 0.68-0.95 0.68-0.95 0.60-0.90 0.56-0.88 0.40-0.77
Cumulative deaths 6 6 8 9 12
Remaining at risk 26 26 24 23 3
patients. Stratified Kaplan-Meier analysis showed a
significant difference in survival after stratifying for
age, with better survival for bilateral LVRS patients (P
= .007, Fig 3, Tables VI and VII).
Twenty-four percent (24/102) of bilateral LVRS had
preoperative FEV1 under 0.5 L/s, compared with 32%
(49/154) of patients who underwent bilateral LVRS.
After stratification for baseline FEV1, patients who
underwent bilateral LVRS had significantly better sur-
vival than did patients who had unilateral LVRS (P =
.003, Fig 4, Tables VIII and IX).
For gender subgroup (female, male) analysis, bilater-
al surgery demonstrated better survival compared with
unilateral (P = .004). For TLC subgroup analysis (>8.5
L, ≤8.5 L), bilateral surgery demonstrated better sur-
vival than unilateral LVRS (P = .01). When patients
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Fig 2. A, Risk subgroup analysis, all study patients with PaO2
≤ 55 mm Hg, unilateral versus bilateral LVRS. B, Risk sub-
group analysis, all study patients with PaO2 > 55 mm Hg, uni-
lateral versus bilateral LVRS.
A
B
Fig 3. A, Risk subgroup analysis, all study patients over 70
years old at time of surgery, unilateral versus bilateral LVRS.
B, Risk subgroup analysis, all study patients 70 years old or
younger at time of surgery, unilateral versus bilateral LVRS.
A
B
Table V. PaO2 > 55 mm Hg (torr)
6 mo 182 d 12 mo 365 d 18 mo 547 d 24 mo 730 d 36 mo 1095 d
Unilateral LVRS
Cumulative survival 0.95 0.94 0.92 0.89 0.8
95% CI 0.90-1.00 0.88-1.00 0.86-0.99 0.81-0.97 0.70-0.90
Cumulative deaths 3 4 5 7 12
Remaining at risk 61 60 59 57 39
Bilateral LVRS
Cumulative survival 0.97 0.93 0.92 0.91 0.87
95% CI 0.95-1.00 0.88-0.98 0.87-0.97 0.85-0.96 0.81-0.94
Cumulative deaths 3 8 9 11 14
Remaining at risk 113 108 107 95 18
were stratified by baseline RV (>5.5 L, ≤5.5 L),
patients who received bilateral LVRS again had better
survival than patients who received unilateral surgery
(P = .005). For the date of surgery (after May 1, 1995),
stratified Kaplan-Meier analysis showed a significant
advantage for bilateral surgery (P = .002).
In an attempt to simultaneously control for patient
heterogeneity and any baseline differences between
the two surgery groups, we analyzed data using the
Cox regression analysis. After adjusting for all covari-
ables (propensity score, age, gender, FEV1, PaO2,
FVC, TLC, RV, and surgery date) in a proportional
hazards model, the hazard ratio for unilateral LVRS
compared with bilateral surgery was 2.00 (P = .05,
95% CI 1.02-3.92). No significant interactions existed
between surgery type and the other risk factors in the
model.
Baseline characteristics and lung function studies.
Baseline characteristics revealed statistically signifi-
cant differences between patients who underwent uni-
lateral and patients who underwent bilateral procedures
in PaO2 (Table I). In general, patients who underwent
unilateral procedures did not have more severe disease
than those who underwent bilateral procedures.
Lung function. Follow-up pulmonary function
results are available on 108 patients (40% of total pop-
ulation) at 2 years ± 6 months after the date of the oper-
ation. Sixty-nine of these patients had bilateral thora-
coscopic staple LVRS, whereas 39 had unilateral
thoracoscopic staple LVRS.
Two years after unilateral LVRS, mean improvement
in FEV1 was 77 mL, while mean improvement in FVC
was 301 mL above preoperative levels. Mean FEV1
was 731 mL preoperatively and rose to 808 mL 2 years
after the operation. Mean FVC was 2.232 L preopera-
tively and rose to 2.533 L 2 years after the operation.
Average follow-up time after unilateral LVRS until pul-
monary function testing was 24.6 months.
Two years after bilateral LVRS, mean improvement
in FEV1 was 274 mL, while mean improvement in
FVC was 711 mL above preoperative levels. Mean
FEV1 was 666 mL preoperatively and rose to 940 mL
2 years after the operation. Mean FVC was 2.040 L
preoperatively and rose to 2.751 L 2 years after the
operation. Average follow-up time after bilateral LVRS
until pulmonary function testing was 23.2 months.
Discussion
Bilateral staple LVRS has been shown in numerous
studies to immediately improve objective pulmonary
function and improve subjective dyspnea.1,3,4,7-12
Bilateral staple LVRS appears superior to unilateral
staple LVRS in achieving these benefits in short-term
follow-up, with similar operative morbidity and mor-
tality.7-11,13-20 Longer term outcome information is
needed before definitive conclusions can be drawn
regarding the overall value of unilateral versus bilater-
al LVRS in severe emphysema patients.
This study shows significant and substantially greater
survival at an average of more than 2 years’ follow-up
of patients who underwent bilateral, compared with uni-
lateral, LVRS. Two-year mortality was 13.6% for bilat-
eral LVRS patients and 27.4% for the unilaterally treat-
ed patients (P = .001). There are a number of possible
reasons for this apparently greater survival after bilater-
al procedures. Pulmonary function improvements are
greater after bilateral LVRS, compared with unilateral
procedures.1,7-10,17 The effects of greater improvements
in oxygenation, lung, diaphragmatic, chest wall,
dynamic hyperinflation, and respiratory muscle func-
tion,2,11,21-25 or all of the above, may contribute to supe-
rior survival after bilateral LVRS (Table II).
FEV1 has been shown to correlate with survival in
patients with emphysema in previous studies.21,22
Patients undergoing bilateral staple LVRS demonstrate
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Fig 4. A, Risk subgroup analysis, all study patients with
FEV1 ≤ 0.5 L/s, unilateral versus bilateral LVRS. B, Risk
subgroup analysis, all study patients with FEV1 > 0.5, unilat-
eral versus bilateral LVRS.
A
B
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Table VI. Age > 70 years
6 mo 182 d 12 mo 365 d 18 mo 547 d 24 mo 730 d 36 mo 1095 d
Unilateral LVRS
Cumulative survival 0.82 0.80 0.78 0.71 0.53
95% CI 0.71-0.93 0.68-0.92 0.66-0.90 0.58-0.84 0.38-0.68
Cumulative deaths 8 9 10 13 21
Remaining at risk 37 36 35 32 17
Bilateral LVRS
Cumulative survival 0.9 0.84 0.78 0.76 0.7
95% CI 0.82-0.98 0.74-0.94 0.67-0.90 0.64-0.88 0.56-0.84
Cumulative deaths 5 8 11 12 14
Remaining at risk 45 42 39 37 5
Table VII. Age ≤ 70 years
6 mo 182 d 12 mo 365 d 18 mo 547 d 24 mo 730 d 36 mo 1095 d
Unilateral LVRS
Cumulative survival 0.88 0.85 0.8 0.76 0.72
95% CI 0.80-0.96 0.76-0.94 0.69-0.90 0.65-0.87 0.61-0.84
Cumulative deaths 7 9 12 14 16
Remaining at risk 52 50 47 45 31
Bilateral LVRS
Cumulative survival 0.96 0.93 0.92 0.91 0.86
95% CI 0.91-0.99 0.88-0.98 0.87-0.97 0.86-0.97 0.79-0.93
Cumulative deaths 5 7 8 9 13
Remaining at risk 99 97 96 86 17
Table VIII. FEV1 ≤ 0.5 L/s
6 mo 182 d 12 mo 365 d 18 mo 547 d 24 mo 730 d 36 mo 1095 d
Unilateral LVRS
Cumulative survival 0.83 0.79 0.67 0.63 0.5
95% CI 0.68-0.98 0.63-0.95 0.48-0.86 0.43-0.82 0.30-0.70
Cumulative deaths 4 5 8 9 12
Remaining at risk 20 19 16 15 9
Bilateral LVRS
Cumulative survival 0.90 0.86 0.82 0.82 0.76
95% CI 0.81-0.98 0.76-0.96 0.71-0.93 0.71-0.93 0.64-0.89
Cumulative deaths 5 7 9 9 11
Remaining at risk 44 42 40 37 6
Table IX. FEV1 > 0.5 L/s
6 mo 182 d 12 mo 365 d 18 mo 547 d 24 mo 730 d 36 mo 1095 d
Unilateral LVRS
Cumulative survival 0.88 0.86 0.85 0.79 0.7
95% CI 0.81-0.96 0.78-0.94 0.77-0.93 0.71-0.88 0.59-0.80
Cumulative deaths 9 11 12 16 23
Remaining at risk 69 67 66 62 39
Bilateral LVRS
Cumulative survival 0.95 0.92 0.91 0.86 0.83
95% CI 0.91-0.99 0.87-0.96 0.86-0.97 0.83-0.95 0.75-0.91
Cumulative deaths 5 8 9 12 16
Remaining at risk 100 97 96 86 16
superior sustained improvements in FEV1 and FVC at
2-year follow-up that may explain the improved overall
survival. In previous analyses of bilateral LVRS
patients, we found that patients with greatest short-term
improvement in pulmonary function tests have better
long-term survival.6 In the current study, FEV1 for
these patients was 274 mL above baseline, compared
with only 77 mL above baseline in the unilateral LVRS
patients 2 years after bilateral LVRS. These findings
are limited by the fact that less than half of the study
population had complete follow-up spirometry at 2
years. Therefore, these values may not be truly repre-
sentative of the total study population. Nonetheless, the
differences in overall survival between unilateral and
bilateral LVRS patients are seen both in the short-term
and the long-term. This may reflect improved ability to
survive the acute morbidity of surgery, as well as the
longer term pulmonary function benefits of more
extensive resection.
The patients who underwent unilateral procedures
were not randomized. Therefore, it is a theoretical pos-
sibility that preoperative patient selection characteris-
tics could have favored patients undergoing bilateral
surgery and thus explain superior long-term survival
after bilateral LVRS. Nevertheless, we do not think
procedure choice was based on the preoperative level of
overall comorbidity. Further, the majority of the unilat-
eral surgeries were performed early in our experience
with LVRS. Unilateral LVRS were performed most
commonly later in our experience for patients with
clear unilateral disease. When patients were stratified
by covariables known to be associated with survival
and data were analyzed by stratified Kaplan-Meier
analysis and log-rank tests, differences between bilater-
al and unilateral LVRS remained significant. Also, the
consistent pattern shown in the univariate analyses
strongly supports the survival advantage associated
with bilateral surgery in this group of patients.
Overall 2-year survival in bilateral LVRS patients in
this series (86%) is similar, but not identical to 2-year
survival we recently reported in patients who under-
went bilateral staple LVRS at this center (81%).6 The
slight differences in reported survival arise from exclu-
sion in the current study of patients who underwent
median sternotomy and exclusion of patients who
underwent surgery less than 2 years ago.
Overall longer term survival has not been previously
reported comparing unilateral with bilateral LVRS pro-
cedures. Short-term lung function response results
favor bilateral procedures but do not necessarily pre-
dict long-term response. Such information is impor-
tant since the upcoming NIH-sponsored National
Emphysema Treatment Trial examines only bilateral
procedures, assuming they are superior to unilateral
procedures overall. The current study suggests that
long-term survival outcome also favors bilateral LVRS.
Thus far, there has been only 1 study to demonstrate
overall survival benefit from LVRS compared with
conventional medical management.26 The current study
does not have a medical control arm for direct compar-
ison of LVRS survival effects. However, we believe this
study provides further, albeit indirect, evidence to sug-
gest that bilateral LVRS may improve overall survival
by the following reasoning. If findings from this study
are confirmed in other centers, there are at least 2 pos-
sible interpretations why bilateral LVRS may be asso-
ciated with significantly improved survival, compared
with unilateral procedures: (1) bilateral procedures
improve overall survival, or (2) both procedures reduce
survival, but bilateral procedures cause less survival
deterioration than unilateral procedures. While the lat-
ter explanation is possible, it is unlikely that more
extensive bilateral procedures would cause less damage
than more limited unilateral procedures if both are
detrimental. Thus, the most likely explanation for the
significantly greater bilateral LVRS outcome is due to
overall improvement in survival from bilateral LVRS.
Thus, while these data are suggestive of overall sur-
vival benefits after bilateral LVRS, a controlled study
would be needed for definitive proof.
In summary, bilateral staple LVRS appears to be
superior to unilateral staple LVRS for the treatment of
severe heterogeneous emphysema and can be accom-
plished safely by using a video-assisted approach.
While prior studies have documented the superior acute
palliative effects of bilateral staple LVRS over unilater-
al staple, the present study documents superior survival
2 years after bilateral staple LVRS.
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